Edwards Lifesciences (EW) Drops 2.80% Amid 3-Day Decline

Edwards Lifesciences (EW) shares fell 2.80% today, marking the third consecutive day of decline, with a total drop of 8.10% over the past three days. The stock price hit its lowest level since November 2024, experiencing an intraday decline of 3.74%.

Edwards Lifesciences Corp (EW) reported a robust 9% sales growth for 2024, driven by the TMTT segment and strategic acquisitions, despite facing regional challenges. This strong performance in sales growth is a significant factor contributing to the company's overall financial health and investor confidence.

Morgan Stanley raised their price target for Edwards Lifesciences from $70.00 to $75.00, indicating a positive outlook on the stock. This adjustment reflects the analysts' optimism about the company's future prospects and its ability to navigate market challenges effectively. The increased price target is likely to influence investor sentiment and potentially stabilize or even boost the stock price in the coming days.